Arash Salardini, MD

Assistant Professor of Neurology

Research Departments & Organizations

Neurology: Alzheimer's Disease Research Center (ADRC) | Clinical Neurosciences Imaging Center (CNIC)

Center for Neuroepidemiology and Clinical Neurological Research

Research Interests

Alzheimer Disease; Early Diagnosis

Research Summary

Dr. Salardini's main interest is in the early detection of dementia and mild cognitive impairment. Mild cognitive impairment is often the earliest stage of problems with cognition and memory. He is working on an algorithm to predict the risk of developing dementia in patients who have mild cognitive impairment. He is also interested in neuroinflammation and its role in progression of MCI to Alzheimer's disease and the role of neuroplasticity in disease modification in early Alzheimer's disease.

Extensive Research Description

Mild cognitive impairment(MCI) is a stage of cognitive decline in between normal cognition and dementia. The most common type of MCI is related to the deposition of a protein(amyloid) which then may progress to Alzheimer's dementia(AD). What causes this conversion is not known and the animal models of AD do not show this conversion. The clinical picture is also less than complete. Patients with MCI fluctuate in their levels of cognition and we have a small project looking at the psychological influences on this fluctuation to be able to more accurately assess progression in patients with MCI. It is possible that conversion occurs at a critical point when amyloid deposition reaches a particular threshold in particular anatomical distributions. From our prelliminary analyses of data already available this does not seem to be the whole picture. It is also possible that the innate immune system plays a role in this conversion. We are going to be using novel PET scanning methods to probe this possibility.

Clinical Trials

Conditions Study Title
Diseases of the Nervous System, Alzheimer's Disease Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Diseases of the Nervous System, Alzheimer's Disease Study of BHV-4157 in Alzheimer's Disease (T2 Protect AD)
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Hypertension Imaging biomarkers of small vessel disease in diabetic individuals
Alzheimer's Disease Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)
Diseases of the Nervous System, Alzheimer's Disease A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_ (MissionAD2)
Alzheimer's Disease An Open-Label Crenezumab Study in Patients With Alzheimer's Disease (CREAD OLE)
Mental Health & Behavioral Research, Alzheimer's Disease Synaptic Density PET tracer evaluation
Mental Health & Behavioral Research Clinical Evaluation of 18F-AV-1451
Alzheimer's Disease A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants with Mild to Moderate Alzheimer s Disease
Alzheimer's Disease CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
Alzheimer's Disease Apathy in Dementia Methylphenidate Trial 2 (ADMET2)
Diseases of the Endocrine System Investigating the Role of the Polyol Pathway in the Central Nervous System

Selected Publications

See list of PubMed publications

Edit this profile

Contact Info

Arash Salardini, MD
Mailing Address
NeurologyPO Box 208018
New Haven, CT 06520-8018
Examples of imaging from our patients

A shows reduction in dopamine innervation in the basal ganglia of a patient with Lewy Body Disease. B shows a negative amyloid scan with Florbetapir where most of the binding is non-specifically to the white matter. C shows specific amyloid binding in the cortex. D shows an FDG PET which shows temporoparietal hypometabolism consistent with AD. Compare with the normal uptake in F. The corresponding MRI in G shows shrinkage in the area of brain responsible for memories.. E shows asymmetrical reduction in the frontal and parietal cortices consistent with frontotemporal dementia. The corresponding MRI image shows asymmetrical atrophy of temporal pole and the “knife edge” sign. I shows preferential atrophy of parietal lobe and widening of the posterior cortical sulci consistent with early posterior cortical atrophy which is a type of Alzheimer's disease.

The Hospital Neurology Book

A new textbook to be published in 2016, approaches the diagnosis and treatment of neurological disease from a practical and epidemiologically appropriate perspective. It also deals with common medical problems faced by neurology inpatients.